Objetivo Tumours escape proper immune response by propagating immune suppression. Immunotherapy aims to enhance anti-tumour immunity. This highly relevant research area arose recently from advantages in immunology, genetics and oncology. Currently, immunotherapeutics are either protein (e.g. antibodies) or cell-based (e.g. cancer vaccines) and promising approaches target immune checkpoint control, a mechanism crucial for anti-tumour T cell activity.Here, development of a completely new class of immunotherapeutics based on advantageous oligonucleotides is proposed.To this aim, oligonucleotides will be designed to modulate expression of receptor genes involved in immune checkpoint control (e.g. PD-L1, CTLA4) and thus block tumour-mediated T cell inhibition. Of special interest will be the employment of the exon skipping technique to reduce surface receptor and potentially induce antagonistic soluble isoforms.To ensure delivery of oligonucleotides, liposomal or polycationic nanoparticles will be utilized as previous studies demonstrated good tissue bioavailability, e.g. for PTO-antisense RNA and polyethylenimine. Oligonucleotides will be tested for functionality, efficacy and non-toxicity in vitro. To facilitate practical clinical application of the developed drugs, most promising candidates will then be applied to pre-clinical tumour models in vivo. Charmingly, this novel technique will also be applied ex vivo to enhance anti-cancer cell therapy, thus evading systemic distribution.Collaboration of two world-renowned scientific institutions, the German Fraunhofer society and Canadian partner McMaster University, will ensure a prolific environment for successful project conclusion and allow considerable advancement of the career of a most promising European researcher. Furthermore, the project will support development of a key technology in the important field of cancer therapy, thus providing a significant competitive advantage for European interests in health research. Ámbito científico medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccinesmedical and health sciencesclinical medicineoncologynatural sciencesbiological sciencesgeneticsRNAmedical and health sciencesbasic medicineimmunologyimmunotherapymedical and health sciencesmedical biotechnologycells technologies Programa(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Tema(s) MSCA-IF-2015-GF - Marie Skłodowska-Curie Individual Fellowships (IF-GF) Convocatoria de propuestas H2020-MSCA-IF-2015 Consulte otros proyectos de esta convocatoria Régimen de financiación MSCA-IF-GF - Global Fellowships Coordinador FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV Aportación neta de la UEn € 243 352,80 Dirección HANSASTRASSE 27C 80686 Munchen Alemania Ver en el mapa Región Bayern Oberbayern München, Kreisfreie Stadt Tipo de actividad Research Organisations Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 243 352,80 Socios (1) Ordenar alfabéticamente Ordenar por aportación neta de la UE Ampliar todo Contraer todo Socio Las organizaciones asociadas contribuyen a la aplicación de la acción, pero no firman el acuerdo de subvención. MCMASTER UNIVERSITY Canadá Aportación neta de la UEn € 0,00 Dirección 1280 MAIN ST WEST L8S 4L8 Hamilton Ver en el mapa Tipo de actividad Higher or Secondary Education Establishments Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 157 622,40